News

Pharmabiz1d
Pasithea completes enrollment and initial dosing of first Cohort from its phase 1/1b trial of PAS-004 in adult NF1 patients
Pasithea completes enrollment and initial dosing of first Cohort from its phase 1/1b trial of PAS-004 in adult NF1 patients: Miami Saturday, August 2, 2025, 18:00 Hrs [IST] Pasith ...
Pharmabiz1d
Medicenna strengthens IP portfolio with five patents granted for its IL-2 and IL-4 Superkines
US Patent No. 12,202,873 – Superagonists, Partial Agonists and Antagonists of IL-2. Also granted in Switzerland, China, Germany, France, United Kingdom, India, and Japan and allowed in Canada with ...
Pharmabiz1d
Plus Therapeutics’ subsidiary, CNSide to launch CNSide cerebrospinal fluid assay platform in US
Plus Therapeutics’ subsidiary, CNSide to launch CNSide cerebrospinal fluid assay platform in US: Houston Saturday, August 2, 2025, 14:00 Hrs [IST] Plus Therapeutics, Inc., a cli ...
Pharmabiz1d
BioDuro & Atombeat enter strategic partnership to launch an AI-powered platform for accelerated peptide drug discovery
BioDuro & Atombeat enter strategic partnership to launch an AI-powered platform for accelerated peptide drug discovery: Irvine, California Saturday, August 2, 2025, 16:00 Hrs [IST ...
Pharmabiz1d
US FDA approves SetPoint Medical’s novel neuroimmune modulation device, SetPoint System for rheumatoid arthritis
US FDA approves SetPoint Medical’s novel neuroimmune modulation device, SetPoint System for rheumatoid arthritis: Valencia, California Saturday, August 2, 2025, 17:00 Hrs [IST] ...
Pharmabiz1d
Marengo Asia Hospitals inks strategic clinical partnership with Metis – The Medicity Hospital, Varanasi
Marengo Asia Hospitals inks strategic clinical partnership with Metis – The Medicity Hospital, Varanasi: Our Bureau, Mumbai Saturday, August 2, 2025, 15:40 Hrs [IST] Marengo Asi ...
Pharmabiz1d
US FDA requires major changes to opioid pain medication labelling to emphasize risks
US FDA requires major changes to opioid pain medication labelling to emphasize risks: Maryland Saturday, August 2, 2025, 11:00 Hrs [IST] The US Food and Drug Administration (FDA) ...
Pharmabiz1d
Mallinckrodt & Endo complete merger to create global, scaled, diversified therapeutics leader
Mallinckrodt & Endo complete merger to create global, scaled, diversified therapeutics leader: Dublin Saturday, August 2, 2025, 09:00 Hrs [IST] Mallinckrodt plc, a leading provide ...
Pharmabiz1d
Fresenius Medical Care’s third-party CRO, Frenova announces strategic collaboration advancing genomics-driven, precision kidney disease care
Fresenius Medical Care’s third-party CRO, Frenova announces strategic collaboration advancing genomics-driven, precision kidney disease care: Bad Homburg Saturday, August 2, 202 ...
Pharmabiz2d
Maxivision Super Speciality Eye Hospital launches 10 super speciality eye hospitals across Chennai
Maxivision Super Speciality Eye Hospitals (Maxivision), one of India's fastest-growing eye care providers, announced its strategic expansion in Chennai with the launch of 10 eye hospitals/vision ...
Pharmabiz2d
Cardiosense receives US FDA 510(k) clearance for its CardioTag device
Cardiosense receives US FDA 510(k) clearance for its CardioTag device: Chicago Friday, August 1, 2025, 17:00 Hrs [IST] Cardiosense, a medical AI company transforming cardiovascula ...
Pharmabiz1d
US FDA grants fast track designation to Revalesio’s lead investigational therapy, RNS60 to treat acute ischemic stroke
US FDA grants fast track designation to Revalesio’s lead investigational therapy, RNS60 to treat acute ischemic stroke: Tacoma, Washington Saturday, August 2, 2025, 15:00 Hrs [I ...